The Cells We Use

SCT’s process begins by taking a sample enriched in antibody secreting B cells, called plasma cells. Plasma cells have undergone affinity maturation, so their antibodies have been selected by the immune system to have higher affinity against their target. Single cells are deposited into thousands of wells in an addressable array.

Our Screening Method

The secreted antibodies from thousands of plasma cells are captured onto slides and the captured antibodies are interrogated for their binding activity. Antibodies can be screened to find relative affinity, subclass, cross-reactivity (e.g. Human and Cynomolgus), and more characteristics depending on your
project needs.

Our Data

Output from the use of AbTheneum™ is displayed as a compendium of Big Data in what is called the Antibody Atlas™. Each study focused on a different target protein has its own proprietary Antibody Atlas™.

The Antibody Atlas™ is a cross-reference of results that can include affinity, kinetics, epitope binding, functional assessment, DNA sequences of the antibody cognate light and heavy chains, and structural inference for each antibody. The resulting relational database presents an easy format in which to expand an antibody screening campaign, and pick the best candidates for downstream characterization.

We Are Different

The overriding goal of therapeutic antibody discovery campaigns is to get a wide selection of high affinity monoclonals representing diverse epitopes to the target of choice. AbTheneum™ is designed to achieve this goal more thoroughly than the technologies commonly used today.

Partner with Single Cell Technology to identify therapeutic antibodies against your target of choice today.